Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Do caregiver profiles predict the use of dementia care services? Findings from the Actifcare study.

Kerpershoek L, Woods B, Wolfs C, Verhey F, Jelley H, Bieber A, Stephan A, Michelet M, Selbaek G, Handels R, Wimo A, Hopper L, Irving K, Marques MJ, Gonçalves-Pereira M, Portolani E, Zanetti O, de Vugt M; and the Actifcare Consortium.

Aging Ment Health. 2018 Dec 6:1-8. doi: 10.1080/13607863.2018.1544215. [Epub ahead of print]

PMID:
30518244
2.

Impact of Untimely Access to Formal Care on Costs and Quality of Life in Community Dwelling People with Dementia.

Janssen N, Handels RL, Sköldunger A, Woods B, Jelley H, Edwards RT, Orrell M, Selbæk G, Røsvik J, Gonçalves-Pereira M, Marques MJ, Zanetti O, Portolani E, Irving K, Hopper L, Meyer G, Bieber A, Stephan A, Kerpershoek L, Wolfs CAG, de Vugt ME, Verhey FRJ, Wimo A; Consortium Actifcare.

J Alzheimers Dis. 2018;66(3):1165-1174. doi: 10.3233/JAD-180531.

PMID:
30400096
3.

Quality of Life, Care Resource Use, and Costs of Dementia in 8 European Countries in a Cross-Sectional Cohort of the Actifcare Study.

Handels RLH, Sköldunger A, Bieber A, Edwards RT, Gonçalves-Pereira M, Hopper L, Irving K, Jelley H, Kerpershoek L, Marques MJ, Meyer G, Michelet M, Portolani E, Røsvik J, Selbaek G, Stephan A, de Vugt M, Wolfs C, Woods B, Zanetti O, Verhey F, Wimo A; and Actifcare consortium.

J Alzheimers Dis. 2018;66(3):1027-1040. doi: 10.3233/JAD-180275.

PMID:
30372674
4.

Cognitive behavioural therapy for anxiety disorders in Parkinson's disease: Design of a randomised controlled trial to assess clinical effectiveness and changes in cerebral connectivity.

Mulders AEP, Moonen AJH, Dujardin K, Kuijf ML, Duits A, Flinois B, Handels RLH, Lopes R, Leentjens AFG.

J Psychosom Res. 2018 Sep;112:32-39. doi: 10.1016/j.jpsychores.2018.04.002. Epub 2018 Apr 10.

PMID:
30097133
5.

Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer's disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol.

Karagiannidou M, Wittenberg R, Landeiro FIT, Park AL, Fry A, Knapp M, Gray AM, Tockhorn-Heidenreich A, Castro Sanchez AY, Ghinai I, Handels R, Lecomte P, Wolstenholme J; ROADMAP Group.

BMJ Open. 2018 Jun 8;8(6):e020638. doi: 10.1136/bmjopen-2017-020638.

6.

Measuring quality of life of people with predementia and dementia and their caregivers: a systematic review protocol.

Landeiro F, Walsh K, Ghinai I, Mughal S, Nye E, Wace H, Roberts N, Lecomte P, Wittenberg R, Wolstenholme J, Handels R, Roncancio-Diaz E, Potashman MH, Tockhorn-Heidenreich A, Gray AM; ROADMAP Group.

BMJ Open. 2018 Mar 30;8(3):e019082. doi: 10.1136/bmjopen-2017-019082.

7.

Resource utilisation and costs in predementia and dementia: a systematic review protocol.

Landeiro F, Wace H, Ghinai I, Nye E, Mughal S, Walsh K, Roberts N, Lecomte P, Wittenberg R, Wolstenholme J, Handels R, Roncancio-Diaz E, Potashman MH, Tockhorn-Heidenreich A, Gray AM; ROADMAP Group.

BMJ Open. 2018 Jan 23;8(1):e019060. doi: 10.1136/bmjopen-2017-019060.

8.

Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.

Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL, Verhey FRJ, Winblad B.

J Alzheimers Dis. 2017;60(4):1477-1487. doi: 10.3233/JAD-170324.

PMID:
29081416
9.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27. Review.

PMID:
29076399
10.

Needs and quality of life of people with middle-stage dementia and their family carers from the European Actifcare study. When informal care alone may not suffice.

Kerpershoek L, de Vugt M, Wolfs C, Woods B, Jelley H, Orrell M, Stephan A, Bieber A, Meyer G, Selbaek G, Handels R, Wimo A, Hopper L, Irving K, Marques M, Gonçalves-Pereira M, Portolani E, Zanetti O, Verhey F; Actifcare Consortium.

Aging Ment Health. 2018 Jul;22(7):897-902. doi: 10.1080/13607863.2017.1390732. Epub 2017 Oct 25.

PMID:
29068697
11.

Challenges and recommendations for the health-economic evaluation of primary prevention programmes for dementia.

Handels R, Wimo A.

Aging Ment Health. 2017 Oct 17:1-7. doi: 10.1080/13607863.2017.1390730. [Epub ahead of print]

PMID:
29039976
12.

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.

Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):285-295. doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27. Review.

13.

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.

Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27. Review.

14.

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers.

Handels RLH, Vos SJB, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, Oleksik A, Pirtosek Z, Scheltens P, Soininen H, Teunissen C, Tsolaki M, Wallin AK, Winblad B, Verhey FRJ, Visser PJ.

Alzheimers Dement. 2017 Aug;13(8):903-912. doi: 10.1016/j.jalz.2016.12.015. Epub 2017 Feb 17.

PMID:
28216393
15.

Caregiver profiles in dementia related to quality of life, depression and perseverance time in the European Actifcare study: the importance of social health.

Janssen EP, de Vugt M, Köhler S, Wolfs C, Kerpershoek L, Handels RL, Orrell M, Woods B, Jelley H, Stephan A, Bieber A, Meyer G, Engedal K, Selbaek G, Wimo A, Irving K, Hopper L, Gonçalves-Pereira M, Portolani E, Zanetti O, Verhey FR.

Aging Ment Health. 2017 Jan;21(1):49-57. doi: 10.1080/13607863.2016.1255716. Epub 2016 Nov 21.

PMID:
27869480
16.

Erratum to: Access to timely formal dementia care in Europe: protocol of the Actifcare (ACcess to Timely Formal Care) study.

Kerpershoek L, de Vugt M, Wolfs C, Jelley H, Orrell M, Woods B, Stephan A, Bieber A, Meyer G, Engedal K, Selbaek G, Handels R, Wimo A, Hopper L, Irving K, Marques M, Gonçalves-Pereira M, Portolani E, Zanetti O, Verhey F; Actifcare Consortium.

BMC Health Serv Res. 2016 Oct 28;16(1):620. No abstract available.

17.

The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients.

Jansen WJ, Handels RL, Visser PJ, Aalten P, Bouwman F, Claassen J, van Domburg P, Hoff E, Hoogmoed J, Leentjens AF, Rikkert MO, Oleksik AM, Smid M, Scheltens P, Wolfs C, Verhey F, Ramakers IH.

J Alzheimers Dis. 2017;55(2):679-689.

PMID:
27716658
18.

Access to timely formal dementia care in Europe: protocol of the Actifcare (ACcess to Timely Formal Care) study.

Kerpershoek L, de Vugt M, Wolfs C, Jelley H, Orrell M, Woods B, Stephan A, Bieber A, Meyer G, Engedal K, Selbaek G, Handels R, Wimo A, Hopper L, Irving K, Marques M, Gonçalves-Pereira M, Portolani E, Zanetti O, Verhey F; Actifcare Consortium.

BMC Health Serv Res. 2016 Aug 23;16(1):423. doi: 10.1186/s12913-016-1672-3. Erratum in: BMC Health Serv Res. 2016 Oct 28;16(1):620.

19.

Combinations of Service Use Types of People With Early Cognitive Disorders.

Janssen N, Handels RL, Koehler S, Ramakers IH, Hamel RE, Olde Rikkert MG, Scheltens P, Bouwman FH, van der Flier WM, Wolfs CA, de Vugt ME, Evers SM, Verhey FR.

J Am Med Dir Assoc. 2016 Jul 1;17(7):620-5. doi: 10.1016/j.jamda.2016.02.034. Epub 2016 Apr 9.

PMID:
27073042
20.

Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort.

Handels RL, Joore MA, Vos SJ, Aalten P, Ramakers IH, Rikkert MO, Scheltens P, Jansen WJ, Visser PJ, van Berckel BM, van Domburg P, Smid M, Hoff E, Hoogmoed J, Bouwman F, Claassen J, Leentjens AF, Wolfs CA, Severens JL, Verhey FR.

J Alzheimers Dis. 2016 Mar 31;52(3):875-85. doi: 10.3233/JAD-151120.

PMID:
27031483

Supplemental Content

Loading ...
Support Center